Pulmonary Surfactant Market

Pulmonary surfactant is a substance that improves lung function. It decreases the amount of fluid entering and leaving the lungs, thereby improving breathing. Pulmonary surfactant is produced by heating sheep or cow's milk to above 85 degrees Fahrenheit and then separating out the proteins. The resultant liquid is referred to as a "fluorosurfactant" because its surface resembles water waves.

Pulmonary resuscitation (PR) uses surfactant drives and restraints to improve the way oxygen moves through the body and the way the body breathes on its own. Between 2018 and 2031, the market for pulmonary surfactant drivers is expected to grow at a CAGR of **%.

Asia-Pacific is the region with the highest growth rate for pulmonary surfactant therapies. The market will increase from $** billion in 2018 to $** billion by 2031.

The pulmonary surface agent market will likely come in second place in terms of value to the inhalation solution market.COPD and other respiratory diseases come in second and third place, respectively, in terms of value in the application market segment for asthma. Europe, Asia-Pacific, and the rest of the world are thought to be the next most valuable regions after North America.

Amgen Inc., EMD Serono AG, Filtration Corporation of America, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., ResMed, Sandoz Ltd., and Synthetic Biologics Corporation are the key players in the pulmonary surfactant market.